Esperion Therapeutics (ESPR) Asset Utilization Ratio (2019 - 2026)

Esperion Therapeutics has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.9 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio rose 15.91% year-over-year to 0.9; the trailing twelve-month figure through Mar 2026 stood at 0.9 (up 15.91% YoY), and the FY2025 full-year result was 1.0, down 17.66% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.9, down from 0.97 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 1.01 in Q4 2024, with the low at 0.21 in Q2 2022.
• Historically, Asset Utilization Ratio has averaged 0.61 across 5 years, with a median of 0.77 in 2024.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio sank 66.67% — and 2024, when it soared 144.97%.
• Esperion Therapeutics' Asset Utilization Ratio stood at 0.27 in 2022, then jumped by 102.37% to 0.54 in 2023, then soared by 85.43% to 1.01 in 2024, then fell by 3.83% to 0.97 in 2025, then decreased by 7.26% to 0.9 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.9 (Q1 2026), 0.97 (Q4 2025), and 0.85 (Q3 2025), per Business Quant data.